Five-year U.K. breast cancer trial starts

Jan 16, 2008

Two British charities are joining to initiate the first U.K.-based clinical trial for women with a specific aggressive form of breast cancer.

Breakthrough Breast Cancer and Cancer Research U.K. said the "Triple-Negative Trial" aims to improve breast cancer treatment for women with hormone and HER2 negative tumors, sometimes referred to as triple negative because they lack hormone (oestrogen and progesterone) and HER2 receptors. Such cancers are more common among younger women and those of African ethnicity.

More than 44,000 U.K. women are diagnosed with breast cancer annually, with triple negative tumors accounting for between 15 percent and 20 percent of them. Triple negative tumors do not respond to targeted treatments such as tamoxifen. The new clinical trial is designed to develop a more tailored and effective chemotherapy treatment for such cancers.

The five-year trial will be led by Dr. Andrew Tutt, director of the Breakthrough Breast Cancer Research Unit at King's College London.

Breakthrough Breast Cancer and Cancer Research U.K. are jointly funding the trial with Britain's Institute of Cancer Research and King's College London.

Copyright 2008 by United Press International

Explore further: Breast cancer treatments more effective now than in the past

add to favorites email to friend print save as pdf

Related Stories

Better diagnostic imaging for traumatic brain injuries

Oct 27, 2014

Image-calibration technology designed and developed by scientists at the National Institute of Standards and Technology (NIST) in collaboration with the National Cancer Institute and the Radiological Society ...

Quality of life measures in breast cancer clinical trials

Jan 07, 2011

Quality of life measures tend to be most useful for clinical decision-making in trials in which quality of life is the primary outcome, according to a recent study published online January 7 in The Journal of the National Ca ...

Recommended for you

Gene test aids cancer profile

7 hours ago

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

Hospital volume not linked to costs of cancer surgery

22 hours ago

(HealthDay)—Hospital surgical volume does not appear to correlate with Medicare payments for cancer surgery, according to research published online Nov. 24 in the Journal of Clinical Oncology.

How a common antacid could lead to cheaper anti-cancer drugs

Nov 26, 2014

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want t ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.